Q1 Earnings Forecast for BBIO Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of BridgeBio Pharma in a note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($0.73) per share for the quarter. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.85 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million.

Other research analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Citigroup increased their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Bank of America lifted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Finally, Evercore ISI lifted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.67.

BridgeBio Pharma Stock Down 5.2 %

BBIO stock opened at $34.35 on Wednesday. The business has a 50 day moving average of $32.20 and a 200-day moving average of $28.13. The firm has a market cap of $6.53 billion, a PE ratio of -12.05 and a beta of 1.07. BridgeBio Pharma has a 12-month low of $21.62 and a 12-month high of $39.47.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 326,932 shares of BridgeBio Pharma stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the sale, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian C. Stephenson sold 68,000 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $2,467,720.00. Following the completion of the transaction, the chief financial officer now owns 93,758 shares in the company, valued at $3,402,477.82. This represents a 42.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,496,239 shares of company stock valued at $122,612,036. 24.66% of the stock is currently owned by corporate insiders.

Institutional Trading of BridgeBio Pharma

A number of large investors have recently modified their holdings of BBIO. Creative Planning purchased a new stake in BridgeBio Pharma in the third quarter valued at approximately $772,000. Allspring Global Investments Holdings LLC increased its holdings in shares of BridgeBio Pharma by 17.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after buying an additional 801 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BridgeBio Pharma by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock valued at $170,000 after buying an additional 1,214 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of BridgeBio Pharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,165 shares of the company’s stock worth $921,000 after acquiring an additional 14,181 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its position in BridgeBio Pharma by 50.8% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company’s stock worth $19,129,000 after acquiring an additional 253,101 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.